AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25599346 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with voriconazole and anidulafungin (post hoc analysis)
Number of subjects: 454
Study 25599346 — intervention group
Group type: COMPARATOR
Intervention: Voriconazole monotherapy (post hoc analysis)
Number of subjects: 454
Study 24622415 — intervention group
Group type: EXPERIMENTAL
Intervention: IL2 at 0.33 MIU/day
Number of subjects: 24
Study 24622415 — intervention group
Group type: EXPERIMENTAL
Intervention: IL2 at 1 MIU/day
Number of subjects: 24
Study 24622415 — intervention group
Group type: EXPERIMENTAL
Intervention: IL2 at 3 MIU/day
Number of subjects: 24
Study 24622415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 22107691 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet-based regimen
Number of subjects: 82
Study 22107691 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (vitamin D and phosphate binders)
Number of subjects: 82
Study 19093921 — intervention group
Group type: EXPERIMENTAL
Intervention: Low to moderate alcohol intake (drinkers)
Number of subjects: 5804
Study 19093921 — intervention group
Group type: COMPARATOR
Intervention: Nondrinkers
Number of subjects: 5804
Study 15959459 — intervention group
Group type: EXPERIMENTAL
Intervention: 12% oxygen (hypoxia) for 18 hours
Number of subjects: 22
Study 15959459 — intervention group
Group type: COMPARATOR
Intervention: 21% oxygen (normoxia) for 18 hours
Number of subjects: 22
Study 12542601 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg lansoprazole (u.i.d) for 14 days
Number of subjects: 30
Study 12542601 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg rebamipide (t.i.d) for 14 days
Number of subjects: 30
Study 12542601 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg famotidine (b.i.d) for 14 days
Number of subjects: 30
Study 12542601 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg roxatidine (b.i.d) for 14 days
Number of subjects: 30
Study 12542601 — intervention group
Group type: COMPARATOR
Intervention: Control group (without medication)
Number of subjects: 30
Study 10632645 — intervention group
Group type: EXPERIMENTAL
Intervention: BTC regimen (colloidal bismuth subcitrate 220 mg b.d., tinidazole 500 mg b.d., clarithromycin 250 mg b.d.)
Number of subjects: 115
Study 10632645 — intervention group
Group type: EXPERIMENTAL
Intervention: OBTC regimen (omeprazole 20 mg daily for 4 weeks with BTC regimen during the first week)
Number of subjects: 115
Study 9505989 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5 mg)
Number of subjects: 9
Study 9505989 — intervention group
Group type: COMPARATOR
Intervention: Imipramine (75 mg)
Number of subjects: 9
Study 9505989 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5 mg) and Imipramine (75 mg) (combined)
Number of subjects: 9
Study 8453092 — intervention group
Group type: EXPERIMENTAL
Intervention: MP/IFN (melphalan/prednisone with natural interferon-alpha)
Number of subjects: 335
Study 8453092 — intervention group
Group type: COMPARATOR
Intervention: MP (melphalan/prednisone)
Number of subjects: 335
Study 8453092 — intervention group
Group type: EXPERIMENTAL
Intervention: MP/IFN
Number of subjects: 335
Study 8453092 — intervention group
Group type: COMPARATOR
Intervention: MP
Number of subjects: 335
Study 3090978 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental diet administered by needle‐catheter jejunostomy (NCJ)
Number of subjects: 20
Study 3090978 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 20
Study 29463586 — intervention group
Group type: EXPERIMENTAL
Intervention: Engager intervention plus standard care
Number of subjects: 280
Study 29463586 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 280
Study 27164841 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 172
Study 27164841 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol succinate
Number of subjects: 172
Study 27164841 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol
Number of subjects: 172
Study 24560331 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week rehabilitation training program (RT)
Number of subjects: 45
Study 24560331 — intervention group
Group type: COMPARATOR
Intervention: Standard follow up (CON)
Number of subjects: 45
Study 21935753 — intervention group
Group type: EXPERIMENTAL
Intervention: Seeing a physician in the past year
Number of subjects: 4021
Study 21935753 — intervention group
Group type: EXPERIMENTAL
Intervention: Being asked about drinking by a physician
Number of subjects: 4021
Study 21935753 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice about safe drinking levels
Number of subjects: 4021
Study 21935753 — intervention group
Group type: EXPERIMENTAL
Intervention: Exceeding low-risk drinking guidelines (ages 18-25)
Number of subjects: 4021
Study 21935753 — intervention group
Group type: EXPERIMENTAL
Intervention: Exceeding low-risk drinking guidelines (ages 26-39)
Number of subjects: 4021
Study 21935753 — intervention group
Group type: EXPERIMENTAL
Intervention: Being asked about drinking (ages 18-25)
Number of subjects: 4021
Study 21935753 — intervention group
Group type: EXPERIMENTAL
Intervention: Being asked about drinking (ages 26-39)
Number of subjects: 4021
Study 20532651 — intervention group
Group type: EXPERIMENTAL
Intervention: Veterans
Number of subjects: 360
Study 20532651 — intervention group
Group type: COMPARATOR
Intervention: Non-veterans
Number of subjects: 360
Study 18657739 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular sufentanil (5 microg) with ropivacaine (100 mg) and clonidine (1 microg/kg)
Number of subjects: 120
Study 18657739 — intervention group
Group type: COMPARATOR
Intervention: Control group with ropivacaine (100 mg) and clonidine (1 microg/kg) without sufentanil
Number of subjects: 120
Study 16308129 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular follow-up by the nutrition team (weekly in hospital, monthly after discharge)
Number of subjects: 112
Study 16308129 — intervention group
Group type: COMPARATOR
Intervention: No specific nutrition team input (control group)
Number of subjects: 112
Study 12549816 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly mail-based educational intervention to patients and prescribers regarding medication adherence (intervention group)
Number of subjects: 9564
Study 12549816 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 9564
Study 12549816 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly mail-based educational intervention
Number of subjects: 9564
Study 12549816 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 9564
Study 10367596 — intervention group
Group type: EXPERIMENTAL
Intervention: L-DOPA (0.10 g, p.o., t.i.d., for 1 day)
Number of subjects: 11
Study 10367596 — intervention group
Group type: EXPERIMENTAL
Intervention: L-DOPA (0.25 g, p.o., t.i.d., for 2 days)
Number of subjects: 11
Study 10367596 — intervention group
Group type: EXPERIMENTAL
Intervention: L-DOPA (both doses)
Number of subjects: 11
Study 10367596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 8754370 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with goitre
Number of subjects: 294
Study 8754370 — intervention group
Group type: COMPARATOR
Intervention: Control group (children without goitre)
Number of subjects: 294
Study 8389333 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (60 mg/day)
Number of subjects: 38
Study 8389333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 3430499 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefonicid (1-g intravenous dose after cord clamping)
Number of subjects: 139
Study 3430499 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin (2-g intravenous dose after cord clamping and at 6, 12, and 18 hours postpartum)
Number of subjects: 139
Study 30630805 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine + Bifid Triple Viable Capsules
Number of subjects: 120
Study 30630805 — intervention group
Group type: COMPARATOR
Intervention: Mesalazine (Control)
Number of subjects: 120
Study 26197940 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term oral immunotherapy (OIT) with Cry j1-galactomannan conjugate
Number of subjects: 47
Study 26197940 — intervention group
Group type: COMPARATOR
Intervention: Control group (no OIT)
Number of subjects: 47
Study 28509487 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 78
Study 28509487 — intervention group
Group type: EXPERIMENTAL
Intervention: Lozartan potassium
Number of subjects: 78
Study 28509487 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of perindopril and lozartan potassium
Number of subjects: 78
Study 28509487 — intervention group
Group type: COMPARATOR
Intervention: Long-term monotherapy with perindopril
Number of subjects: 78
Study 23684755 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 466
Study 23684755 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate
Number of subjects: 466
Study 21131668 — intervention group
Group type: EXPERIMENTAL
Intervention: 9.5 mg/24 h rivastigmine patch
Number of subjects: 0
Study 21131668 — intervention group
Group type: EXPERIMENTAL
Intervention: 17.4 mg/24 h rivastigmine patch
Number of subjects: 0
Study 21131668 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 to 12 mg/d rivastigmine capsules
Number of subjects: 0
Study 21131668 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine patch groups
Number of subjects: 0
Study 21131668 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine-treated groups
Number of subjects: 0
Study 21131668 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine patch
Number of subjects: 0
Study 21131668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18427220 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-point injection of botulinum toxin A into one site
Number of subjects: 17
Study 18427220 — intervention group
Group type: COMPARATOR
Intervention: Multiple-points injection of botulinum toxin A into two sites on both heads of the gastrocnemius
Number of subjects: 17
Study 18427220 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-point injection of botulinum toxin A
Number of subjects: 17
Study 16583205 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 12791614 — intervention group
Group type: EXPERIMENTAL
Intervention: Original wheat germ containing 328 mg phytosterols
Number of subjects: 10
Study 12791614 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytosterol-free wheat germ
Number of subjects: 10
Study 12791614 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat germ with extracted-and-reconstituted phytosterol
Number of subjects: 10
Study 10592853 — intervention group
Group type: EXPERIMENTAL
Intervention: FemCap with 2% nonoxynol-9 spermicide
Number of subjects: 841
Study 10592853 — intervention group
Group type: COMPARATOR
Intervention: Ortho All-Flex diaphragm with 2% nonoxynol-9 spermicide
Number of subjects: 841
Study 10592853 — intervention group
Group type: EXPERIMENTAL
Intervention: FemCap
Number of subjects: 841
Study 10592853 — intervention group
Group type: COMPARATOR
Intervention: FemCap and Ortho All-Flex diaphragm
Number of subjects: 841
Study 7697242 — intervention group
Group type: EXPERIMENTAL
Intervention: BiPAP ventilatory assistance using a non‐rebreather valve and volume cycled ventilation
Number of subjects: 0
Study 7697242 — intervention group
Group type: COMPARATOR
Intervention: BiPAP ventilatory assistance using a standard exhalation device
Number of subjects: 0
Study 7697242 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of a new plateau exhalation device or a non‐rebreather valve
Number of subjects: 0
Study 7697242 — intervention group
Group type: EXPERIMENTAL
Intervention: Changing exhalation devices
Number of subjects: 0
Study 2666237 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily
Number of subjects: 131
Study 2666237 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 131
Study 338401 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline
Number of subjects: 127
Study 338401 — intervention group
Group type: COMPARATOR
Intervention: Viloxazine
Number of subjects: 127
Study 30637889 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) treatment regimen (2 mA current, 30 min sessions, twice a week for up to 24 weeks)
Number of subjects: 24
Study 30637889 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) treatment
Number of subjects: 24
Study 28816893 — intervention group
Group type: EXPERIMENTAL
Intervention: ON-Q Pain Relief System pump (bupivacaine HCl)
Number of subjects: 200
Study 28816893 — intervention group
Group type: COMPARATOR
Intervention: Exparel (liposomal bupivacaine)
Number of subjects: 200
Study 25771249 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 year multidomain intervention (diet, exercise, cognitive training, vascular risk monitoring)
Number of subjects: 1260
Study 25771249 — intervention group
Group type: COMPARATOR
Intervention: General health advice (control group)
Number of subjects: 1260
Study 23732950 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual stimulation at frequencies below 0.12 Hz
Number of subjects: 12
Study 23732950 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual stimulation at frequencies between 0.12 and 0.25 Hz
Number of subjects: 12
Study 23732950 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual stimulation at frequencies above 0.5 Hz
Number of subjects: 12
Study 21345487 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple therapy (10 days of omeprazole plus a single three-in-one capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline)
Number of subjects: 440
Study 21345487 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (7 days of omeprazole, amoxicillin, and clarithromycin)
Number of subjects: 440
Study 19321567 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine supplementation (2.5 g with each main meal for 3 months)
Number of subjects: 30
Study 19321567 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation (2.5 g with each main meal for 3 months)
Number of subjects: 30
Study 19321567 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine supplementation
Number of subjects: 30
Study 19321567 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 30
Study 17348758 — intervention group
Group type: EXPERIMENTAL
Intervention: Group music therapy carried out once weekly for 2 years
Number of subjects: 0
Study 17348758 — intervention group
Group type: COMPARATOR
Intervention: Nonmusic therapy group
Number of subjects: 0
Study 17348758 — intervention group
Group type: EXPERIMENTAL
Intervention: Group music therapy
Number of subjects: 0
Study 15353506 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting
Number of subjects: 2082
Study 15353506 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 2082
Study 15353506 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine abciximab administration
Number of subjects: 2082
Study 15353506 — intervention group
Group type: COMPARATOR
Intervention: Reperfusion modality (stents or glycoprotein IIb/IIIa inhibitors)
Number of subjects: 2082
Study 11598468 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trials
Number of subjects: 195
Study 11598468 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to conducting surgical randomized controlled trials
Number of subjects: 195
Study 9415962 — intervention group
Group type: EXPERIMENTAL
Intervention: Coloured overlays (10 coloured plastic sheets and 19 pairwise combinations)
Number of subjects: 152
Study 9415962 — intervention group
Group type: EXPERIMENTAL
Intervention: Chosen coloured overlay
Number of subjects: 152
Study 9415962 — intervention group
Group type: EXPERIMENTAL
Intervention: Chosen overlay
Number of subjects: 152
Study 7876011 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic digitalization with digoxin postoperatively
Number of subjects: 65
Study 7876011 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic digitalization (control group)
Number of subjects: 65
Study 2907314 — intervention group
Group type: EXPERIMENTAL
Intervention: Suxamethonium
Number of subjects: 18
Study 2907314 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium
Number of subjects: 18
Study 31504982 — intervention group
Group type: EXPERIMENTAL
Intervention: General recommendations of good oral hygiene including teeth brushing, daily antiseptic mouthwash, and twice a year scaling.
Number of subjects: 472
Study 31504982 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group).
Number of subjects: 472
Study 31504982 — intervention group
Group type: EXPERIMENTAL
Intervention: General recommendations of good oral hygiene.
Number of subjects: 472
Study 31504982 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with baseline periodontal disease who became negative for one red complex bacterium.
Number of subjects: 472
Study 29621986 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-year comprehensive health intervention conducted by each workplace.
Number of subjects: 719
Study 29621986 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention implementation with high quality (scores higher than 4.047 or 4.151 out of 5).
Number of subjects: 719
Study 29621986 — intervention group
Group type: EXPERIMENTAL
Intervention: Health culture measured at 24 months.
Number of subjects: 719
Study 29621986 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical environment quality measured at 12 and 24 months.
Number of subjects: 719
Study 28891408 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib (150 mg twice daily) plus Trametinib (2 mg once daily)
Number of subjects: 870
Study 28891408 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two matched placebo tablets)
Number of subjects: 870
Study 25147225 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline sRAGE levels
Number of subjects: 1218
Study 25147225 — intervention group
Group type: EXPERIMENTAL
Intervention: One interquartile range higher log10-transformed sRAGE
Number of subjects: 1218
Study 23170931 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam 3.75 g/day plus rosuvastatin 5 mg/day (RC, n=20)
Number of subjects: 40
Study 23170931 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin 10 mg (R, n=20)
Number of subjects: 40
Study 21950641 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg (single oral dose)
Number of subjects: 23
Study 21950641 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin 500 mg twice/day for 5 days followed by atorvastatin 20 mg (single oral dose) on day 4
Number of subjects: 23
Study 18483451 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder training and Kegel exercises for 6-8 weeks
Number of subjects: 50
Study 18483451 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 50
Study 16966616 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed brimonidine-timolol (0.2% brimonidine tartrate and 0.5% timolol maleate) twice daily
Number of subjects: 1159
Study 16966616 — intervention group
Group type: COMPARATOR
Intervention: 0.2% brimonidine tartrate 3 times daily
Number of subjects: 1159
Study 16966616 — intervention group
Group type: COMPARATOR
Intervention: 0.5% timolol maleate twice daily
Number of subjects: 1159
Study 16966616 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed brimonidine-timolol
Number of subjects: 1159
Study 16966616 — intervention group
Group type: COMPARATOR
Intervention: Brimonidine
Number of subjects: 1159
Study 16966616 — intervention group
Group type: COMPARATOR
Intervention: Timolol
Number of subjects: 1159
Study 12704946 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste with 1.2% SLS
Number of subjects: 20
Study 12704946 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste with 1.2% SLS and 4% betaine
Number of subjects: 20
Study 12704946 — intervention group
Group type: COMPARATOR
Intervention: Toothpaste with 4% betaine (without SLS)
Number of subjects: 20
Study 11131684 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB
Number of subjects: 0
Study 11131684 — intervention group
Group type: EXPERIMENTAL
Intervention: Androstenedione
Number of subjects: 0
Study 8632219 — intervention group
Group type: EXPERIMENTAL
Intervention: High fiber barley products (50:50 or 80:20 ratios)
Number of subjects: 9
Study 8632219 — intervention group
Group type: COMPARATOR
Intervention: Common barley and oat porridges
Number of subjects: 9
Study 1459516 — intervention group
Group type: EXPERIMENTAL
Intervention: Octylonium bromide 40 mg tid for 4 weeks
Number of subjects: 72
Study 1459516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 6504572 — intervention group
Group type: EXPERIMENTAL
Intervention: Candidin (1:100)
Number of subjects: 37
Study 6504572 — intervention group
Group type: EXPERIMENTAL
Intervention: PHA (2 micrograms)
Number of subjects: 37
Study 30289478 — intervention group
Group type: EXPERIMENTAL
Intervention: Isavuconazole (200 mg IV TID for 2 days, then 200 mg IV OD)
Number of subjects: 400
Study 30289478 — intervention group
Group type: COMPARATOR
Intervention: Caspofungin (70 mg IV OD on day 1, then 50 mg IV OD)
Number of subjects: 400
Study 30289478 — intervention group
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Number of subjects: 400
Study 30289478 — intervention group
Group type: COMPARATOR
Intervention: Caspofungin
Number of subjects: 400
Study 29317186 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma bursts coupled to the trough of theta tACS
Number of subjects: 72
Study 29317186 — intervention group
Group type: COMPARATOR
Intervention: Gamma bursts coupled to the peak of theta tACS
Number of subjects: 72
Study 29317186 — intervention group
Group type: COMPARATOR
Intervention: Gamma tACS continuously superimposed with theta tACS
Number of subjects: 72
Study 26516172 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated intracoronary application of autologous bone marrow-derived cells (BM-MNCs)
Number of subjects: 297
Study 26516172 — intervention group
Group type: COMPARATOR
Intervention: Single BM-MNC application
Number of subjects: 297
Study 26516172 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated BM-MNC application
Number of subjects: 297
Study 25516158 — intervention group
Group type: EXPERIMENTAL
Intervention: ActWell programme (3 months focusing on body weight, physical activity, and alcohol)
Number of subjects: 65